Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application

Dow Jones

04/14

By Christopher Kuo

Praxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults.

Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date.

The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said.

The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 14, 2026 10:32 ET (14:32 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2627442700"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627442700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627442700?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627442700","market":"us","top_or_hot":-1,"title":"Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date. \n</p>\n<p>\n  The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said. \n</p>\n<p>\n  The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 10:32 ET (14:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines Shares Rise After FDA Accepts New Drug Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-14 22:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date. \n</p>\n<p>\n  The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said. \n</p>\n<p>\n  The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 10:32 ET (14:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627442700","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627442700","pubTimestamp":1776177120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Praxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults.Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date.The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LABU":"三倍做多标普生物-Direxion","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","PRAX":"Praxis Precision Medicines, Inc.","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"FDA接受新药申请后Praxis Precision Medicines股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"PRAX":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\nPraxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. \n\n\n  Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date. \n\n\n  The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said. \n\n\n  The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said. \n\n\n \n\n\n   Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 10:32 ET (14:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}